Recent Updates
Recently added Catalysts
PRCT Positive Sentiment

PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026

Key Takeaway: PROCEPT BioRobotics will participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. The event will feature a fireside discussion and in-person meetings. The company focuses on developing robotic solutions for urology, particularly Aquablation therapy for BPH.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a major healthcare conference
  • Focus on advancing patient care in urology
  • Strong clinical evidence with 250 peer-reviewed publications

Full Press Release Details

SAN JOSE, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference in New York City on Wednesday, December 2, 2026, at 3:30 p.m. ET / 12:30 PM PT. The company will also be hosting in person meetings.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Media Contact: Pooja Rao, media@procept-biorobotics.com Investor Contact: Marissa Bych, ir@procept-biorobotics.com

Frequently Asked Questions

When is the Piper Sandler Healthcare Conference?

The conference is on December 2, 2026, at 3:30 p.m. ET.

What will PROCEPT BioRobotics discuss at the conference?

They will participate in a fireside discussion and host meetings.

What is Aquablation therapy?

Aquablation therapy is a robotic treatment for BPH, effective regardless of prostate size.

How many publications support Aquablation therapy?

There are approximately 250 peer-reviewed publications supporting its benefits.

Last updated: Nov 18, 2026